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Objectives. This study sought to assess the efficacy of oral 
sotalol for various arrhythmias n pediatric patients and to
evaluate the incidence of proarrhythmia nd systemic side effects. 
Background. Sotalol is a beta.adrenergic blocking agent with 
additional class III antiarrhythmie properties. Experience i  
pediatric patients is limited. Data concerning the incidence of 
proarrhythmia in children are lacking. 
Methods. Seventy-one pediatric patients (mean age 7.3 years) 
with various supraventricular and ventricular tachyarrhythmias 
were treated with oral sotaiol. All the patients were admitted to 
the hospital for initiation of sotalol therapy. Antiarrhythmic and 
proarrhythmic effects of sotalol were assessed by daily surface 
electrocardiograms (ECGs) during thein-hospital phase and by 
serial Holter monitoring. 
Results. Sotalol was either completely (27 [66%] of 41 patients) 
or partially effective (11[27%] of 41) in 38 (93%) of 41 patients 
with supraventricalar reentrant tachycardias. In patients with 
atrial flutter predominantly after operation for congenital heart 
disease, sotaloi was effective in 84% of patients (completely in 9 of 
19 and partially in 7 of 19). Ventricular tachycardia was com- 
pletely (3 of 11) or partially (4 of 11) controlled in 64% of children. 
Proarrhythmia occurred in seven patients (10%) and consisted of 
symptomatic bradycardia from sinoatrial block and high grade 
atrioventricular (AV) block, respectively, in two children; asymp- 
tomatic high grade AV block in one; torsade de pointes in one; and 
relevant increased ventricular ectopic activity in three. Proar- 
rhythmia required drug discontinuation in four patients. Mean 
duration of treatment for all patients was 18 months (range 1 to
40). 
Conclusions. Sotalol was an effective antiarrhythmic drug for a 
wide range of pediatric tachyarrhytlunias. The considerable num- 
ber of patients with proarrhythmic effects indicates the need for 
initiation of treatment on an inpatient basis and close monitoring 
by serial Holter electrocardiography. 
(J Am CoU Cardio11995;26:1002-7) 
Sotalol hydrochloride is a noncardioselective b ta-adrenergic 
blocking agent with additional class 1II antiarrhythmic proper- 
ties (prolongation of action potential duration) (1,2). Sotalol 
has been proved to be an effective antiarrhythmic agent in 
adult patients treated for ventricular tachyarrhythmias (3-6) 
and atrial flutter (7) and in the short- (8) and long-term 
treatment of supraventricular reentrant tachycardias (9,10). 
The few clinical studies with oral sotalol in the pediatric age 
group have reported encouraging results (11-13), but experi- 
ence with this drug in infants and children is still limited. 
Treatment of adult patients with oral sotalol has been shown to 
be associated with proarrhythmic effects in 3% to 5% of 
patients (2), In pediatric patients the incidence of proarrhyth- 
mia has not been systematically investigated. 
The purpose of the present study was to evaluate prospec- 
tively the effectiveness as well as incidence and type of 
proarrhythmic events in pediatric patients treated with oral 
sotalol. 
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Methods 
Patients. From July 1987 to July 1994, all 71 infants and 
children who were treated at our institution with oral sotalol 
for symptomatic supraventricular nd ventricular rhythmias 
were enrolled in the study protocol. Patients >16 years old 
were included in this study only if they had congenital heart 
disease. 
The study protocol had been approved by the hospital's 
scientific committee. Informed consent was obtained from 
parents of all children included in the study. 
Arrhythmia diagnosis. The type of arrhythmia was diag- 
nosed according to established criteria (14,15) either by 12- 
lead electrocardiography during tachycardia or by 24-h Holter 
electrocardiography, in some instances by transesophageal 
electrocardiography. Invasive electrophysiologic study was per- 
formed for diagnostic purposes in 11 children and for curative 
transcatheter ablation of the underlying arrhythmogenic sub- 
strate in 13. 
Sotaloi protocol. Oral sotalol treatment was started on an 
inpatient basis. Baseline examinations before initiation of 
sotalol included a 12-lead electrocardiogram (ECG), a 24-h 
Holter monitor, echocardiography (two-dimensional and color 
Doppler) and a blood sample for evaluation of renal and liver 
functions as well as a complete blood count. All these tests 
were repeated after 5 to 7 days to sotalol treatment before 
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hospital discharge. Echocardiography was repeated in all pa- 
tients after 3 months of therapy. Blood tests were repeated 
only sporadically and if indicated by the patient's history or 
symptoms. In patients who had been treated with another 
antiarrhythmic drug before, oral sotalol was started after the 
previous antiarrhythmic drug had been discontinued for at 
least five drug half-lives. This condition could not be fulfilled 
for two patients who had been treated with amiodarone before 
the initiation of sotalol. Digoxin was maintained in those 
patients who had already been treated with this substance. 
Oral sotalol was started at a dose of 2 mg/kg body weight per 
day in three divided doses. In case of persistent arrhythmia, the 
dosage was increased in 1- to 2-mg/kg steps under continuous 
ECG monitoring at 3-day intervals until he desired effect or 
the maximal dose of 8 mg/kg per day was reached. Only dose 
adjustments to weight were made on an outpatient basis. 
Increases in dosage for lack of drug effect were made during a 
hospital stay. Determination of serum levels of sotaloi was not 
available during the study. 
Criteria for efficacy. Sotalol treatment was considered suc- 
cessful if the arrhythmia was completely suppressed as evalu- 
ated by symptoms and repeated Holter monitoring. Partial 
effectiveness was defined as a decrease in frequency or dura- 
tion of tachycardias or a reduction in maximal heart rate 
during tachycardia or improvement of symptoms. If a partial 
effect was obtained, dosage was not increased further if 
residual episodes of the arrhythmia were clinically well toler- 
ated and the result was judged satisfactory by the child, the 
parents and the investigators. After initiation of sotalol ther- 
apy, Holter monitoring to evaluate sotalol response was per- 
formed before hospital discharge (usually 5 to 7 days after 
starting sotalol), at 1 month and then at 3- to 6-month intervals 
as well as after dose adjustments on an outpatient basis. 
ECG characteristics. Baseline ECG recordings during si- 
nus rhythm and without any medication except for digoxin 
were compared with those during sotalol therapy for changes 
in duration of PR interval, QRS duration and corrected QT 
interval (QTc) in relation to dosage of sotalol. For better 
comparison of these variables, the ECGs were usually re- 
corded before the following dose of sotalol. The QT interval 
was measured in lead II (16), and rate correction (QTc) was 
calculated according to Bazzett's formula (17). Patients with 
predominantly pacemaker-induced QRS complexes, and pre- 
excitation and the two patients with previous amiodarone 
treatment were excluded from these comparisons. The influ- 
ence of sotalol on heart rate was evaluated by comparing 
minimal and maximal as well as mean heart rate in the 
individual patient during 24-h Holter electrocardiography be-
fore and during sotalol treatment. 
Proarrhythmia was defined as the appearance ofa new type 
of arrhythmia not seen previously in that patient or aggrava- 
tion of a previously observed arrhythmia (18,19). 
Statistics. The relation between increasing dosage of so- 
talol and QTc interval was analyzed using linear regression. A 
modification of the chi-square test (Cochran trend test) was 
used to analyze a linear increase in proportions (proportion of 
Table 1. Patient Data Related to Diagnosis of Underlying 
Rhythm Disturbance 
Structural Heart Disease 
No. of Mean (-SD) No. of 
Diagnosis Pts Age (yr) Pts Type (no. of pts) 
WPW 17 3.8 -+ 4.2 5/17 
PJRT 1 0.1 0 
CAP 16 5.0 -+ 4.0 3/16 
AVNRT 7 9.5 -+ 2.6 1/7 
AFL 19 10.6 -+ 6.4 18/19 
VT 11 9.3 +_ 7.0 6/11 
Total 71 7.3 _+ 5.8 33/71 
Ebstein (3), ASD (1), 
L-TGA (1) 
DORV, s/p (1); SV, s/p 
(1); L-TGA, s/p (1) 
SV/Fontan (1) 
Ebstein, s/p (3); D-TGA/ 
Mustard (10); L-TGA, 
s/p (1); PS, s/p (1); 
Patr, s/p (1); TAPVC, 
s/p (1); ASD, s/p (1) 
IDC (3); myocarditis (1); 
TOF, s/p (1); L-TGA, 
s/p (1) 
AFL = atrial flutter; ASD = atrial septal defect; AVNRT = atrioventricular 
node reentrant tachycardia; CAP = concealed accessory atrioventricular path- 
way; DORV = double-outlet right ventricle; Ebstein = Ebstein's anomaly; 
Fontan =Fontan operation; IDC = idiopathic dilated cardiomyopathy; Mustard 
= Mustard operation; Patr = pulmonary atresia; PJRT = permanent junctional 
reciprocating tachycardia; PS = pulmonary stenosis; Pts (pts) = patients; s/p = 
postoperative; SV = single ventricle; TAPVC = total anomalous pulmonary vein 
connection; TGA - transposition of great arteries; TOF = tetralogy of Fallot; 
VT = ventricular tachycardia; WPW = Wolff-Parkinson-White syndrome. 
patients with QTc prolongation to ->0.44 and to ->0.46 with 
increasing dose of sotalol). Within-patient comparisons were 
made using the paired t test. Independent variables were 
compared using the unpaired t test. A p value <0.05 was 
considered statistically significant. 
Resu l ts  
Patient characteristics. Of the 71 patients (24 female, 47 
male), the diagnosis was supraventricular reentrant tachycar- 
dia in 41 (Wolff-Parkinson-White syndrome in 17, concealed 
accessory pathway in 16, atrioventricular (AV) node reentrant 
tachycardia n 7, permanent junctional reciprocating tachycar- 
dia in 1). Nineteen patients had recurrent episodes of atrial 
flutter (1 congenital, 18 postoperative). Eleven patients had 
ventricular tachycardia. 
Mean [_+SD] age at initiation of sotalol was 7.3 + 5.8 years 
(range 0.1 to 19.9) for the whole group. Mean age was clearly 
lower in patients with Wolff-Parkinson-White syndrome (3.8 
years) and concealed accessory pathway (5 years) than those 
with AV node reentrant tachycardia (9.5 years), atrial flutter 
(10.6 years) or ventricular tachycardia (9.3 years); 16 of the 71 
patients (23%) were <1 year old. Underlying cardiac disease 
was present in 33 of the patients (46%) (structural congenital 
heart disease in 29, idiopathic dilated cardiomyopathy in 3, 
biopsy-proved myocarditis in 1) (Table 1). In 13 patients a 
ventricular demand pacemaker hadpreviously been implanted 
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Table 2. Efficacy of Sotalol for Different Types of Arrhythmias in 71 
Pediatric Patients 
Success (no. of pts) 
Type of No. of Failure Success 
Arrhythmia Pts Complete Partial (no. of pts) Rate (c~) 
Reentrant SVT 
WPW 17 14 2 1 94 
CAP 16 9 6 I 94 
PJRT 1 1 I(X) 
AVNRT 7, 3 3 I 86 
AFL 19 9 7 3 84 
VT 11 3 4 4 64 
Total 71 39 22 10 86 
SVT supraventricular t chycardia: other abbreviations a in "l'able I. 
for sinus node dysfunction after operation for congenital heart 
disease. 
Previous antiarrhythmic treatment. In 51 (70%) of 71 
patients, otalol was used after at least one other antiarrhyth- 
mic drug had failed to control the arrhythmia. In 26 patients 
one antiarrhythmic drug had been used before sotalol; 11 
patients had been treated with two consecutive drugs, 13 with 
three and 1 with four. With increasing experience, sotalol was 
used as the primary antiarrhythmic treatment in 20 (28%) of 
the 71 patients, predominantly for supraventricular reentrant 
tachycardia (16 children) and in 2 with atrial flutter and 
ventricular tachycardia, respectively. 
Sotaiol effectiveness. Forthe whole study group, treatment 
with sotalol was effective in 61 patients (86%); complete 
success was achieved in 39 patients (55%), and partial success 
in 22 (31%). The drug failed to control the arrhythmia n l(I 
patients (14%). Mean dosage was 3.9 _+ 1.6 mg/kg (101 +_ 45 
rag/m2). Mean follow-up of the patients (or duration of therapy 
if already stopped) was 18 months (range 1 to 40). 
Sotalol was most effective in the group of patients with 
supraventricular reentrant achycardias (Wolff-Parkinson- 
White syndrome, concealed accessory pathway, AV node 
reentrant achycardia, permanent junctional reciprocating 
tachycardia), with successful treatment in 38 (93%) of 41 
patients (complete success in 66% and partial effect in 27%). 
Response to sotalol treatment in this group of patients was not 
affected by the presence of underlying heart disease (9 of 41 
children). In this subgroup of patients, complete success was 
also noted in six (67%) of nine patients and partial effect in the 
other three (33%). In patients with atrial flutter, the arrhyth- 
mia was controlled in 16 (84%) of 19 patients (complete 
success in 9 [48%], partial effect in 6 [36%]), and treatment 
failure was seen in 3 (16%,). In children with ventricular 
tachycardia, the arrhythmia was completely suppressed in 3 
(28%) of 11 patients and partially in 4 (36%). The drug failed 
to control ventricular tachycardia in the remaining three 
patients (36%) (Table 2). There was no difference in response 
to sotalol whether there was underlying cardiac disease (two 
failures in six patients) or whether ventricular tachycardia was 
considered i iopathic with an apparently normal heart (two 
failures in five patients). 
(%) 
60- 
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40- 
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Figure 1. Significant increase in proportion of patients wi h QTc 
prolongation to ->0.44 (solid bars, p < 0.01) or >-0.46 (hatched bars, 
p < 0.01) in relation to dosage of sotalol. 
ECG effects. Serial ECGs for comparison were available in 
44 patients. Mean duration of the PR interval was 132 +_ 33 ms 
before sotalol and 134 _+ 33 ms during treatment with sotalol 
(p = NS). Duration of the QRS complex was 89 + 22 ms 
before therapy and 90 _+ 21 ms during treatment (p = NS). For 
these two variables no significant influence of increasing 
dosage was observed. The QTc interval before sotalol was 
0.424 _+ 0.029. Linear regression showed a significant rel tion 
between increasing dosage of sotalol and QTc prolongation 
(R -- 0.357, p = 0.025). When the patients were grouped 
according to whether they received <2, 2 to 4 or >4 mg/kg of 
sotalol, a significant increase in th  proportion of patients with 
QTc prolongation to ->0.44 (p < 0.01) and ->0.46 (p < 0.01) 
was observed (Fig. 1). 
Influence of sotalol on heart rate was evaluated in 34 
patients whose Holter monitors before and during sotalol 
therapy could be compared. Mean heart rate decreased from 
81 _+ 18 beats/rain before sotalol to 75 _+ 12 beats/min during 
sotalol therapy (p < 0.05). Mean minimal heart rate before 
sotalol was 56 _+ 15 beats/rain; during sotalol therapy it 
decreased to 52 _+ 11 beats/rain (p < 0.05). Mean maximal 
heart rate decreased from 162 _+ 27 to 137 _+ 23 beats/rain (p < 
0.01 ). 
Proarrhythmia. In 7 (10%) of 71 patients proarrhythmic 
effects were detected by the surface ECG and serial Holter 
monitors (Table 3). Proarrhythmia led to discontinuation f 
therapy in four children: One infant showed sinoatrial block 
with symptomatic bradycardia (<50 beats/rain); two showed 
asymptomatic increased monomorphic ventricular ectopic ac- 
tivity with ventricular bigeminy and couplets in one and short 
runs of ventricular tachycardia in the other. One child was 
admitted to the hospital with recurrent syncope after treatment 
with sotalol (2 mg/kg perday) for 12 months. On admission 
several episodes of polymorphous ventricular tachycardia of
the torsade de pointes type were documented. Noother factors 
(electrolyte imbalances, concomitant medication) predisposing 
to this type of arrhythmia were found, and these tachycardias 
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Table 3. Characteristics of Patients Who Developed Proarrhythmia 
Pt Age at Dose Onset of 
No. Diagnosis Treatment (mg/kg) Type of Proarrhythmia Outcome Proarrhythmia 
1 WPW I mo 5.3 Sinoatrial block with bradycardia (<50/ S discontinued 4 d 
min) 
2 WPW 1.3 yr 2.0 Torsade de pointes S discontinued 12 mo 
3 WPW 13.3 yr 2.6 Monomorphic ventricular bigeminy and S discontinued 2 d 
couplets 
4 PJRT 1 mo 4.3 Wenckebach-type second-degree AV block; Dose reduction 3 d 
ventricular bigeminy 
5 AVNRT 8.3 yr 4.0 Nonsustained monomorphic VT S discontinued 5 d 
6 AFL/TGA, Mustard 10.9 yr 2.0 High grade AV block PM implantation 2 d 
S continued 
7 AFL/TGA, SPS 19.9 yr 4.5 High grade AV block Dose reduction 2 d 
AV = atrioventricular; d = days; Pt = patient; S = sotalol; SPS = subpulmonary stenosis; other abbreviations as in Table 1. 
were considered a late proarrhythmic effect of sotalol. Because 
of manifest pre-excitation i  the surface ECG, the QT interval 
could not be reliably measured in this patient. No recurrences 
of torsade were observed after withdrawal of sotalol. 
Two patients could be managed by reducing the dosage of 
sotalol. In one patient receiving 4.3 mg/kg of sotalol, the QTc 
interval was markedly prolonged from 0.425 to 0.475, and the 
child showed second-degree AV block of Wenckebach type 
and premature ventricular contractions (bigeminy). In another 
patient receiving 4.5 mg/kg of sotalol, QTc prolongation from 
0.440 to 0.475 occurred, and the boy showed high grade AV 
block in atrial flutter. Dose reduction resulted in disappear- 
ance of the proarrhythmic effect and in normalization of the 
QTc interval in both patients. 
One patient with atrial flutter received 2 mg/kg of sotalol 
and developed high grade AV block with consecutive severe 
symptomatic bradycardia with a minimal heart rate of 23 
beats/min and asystole up to 5 s. This boy required emergency 
external cardioversion and implantation of a pacemaker. So- 
talol was continued afterward. 
The dosage of sotalol in patients with proarrhythmic effects 
(mean 3.5 mg/kg, range 2.0 to 5.3) was not statistically different 
from the mean dosage for the whole group. Because patients 
with manifest pre-excitation orwith pacemaker-induced QRS 
complexes had to be excluded from QT measurements, only 
four of the seven patients with proarrhythmia could be evalu- 
ated for the relation of proarrhythmia to drug-induced QT 
prolongation. In these four patients, baseline QTc values 
before sotalol therapy varied between 0.425 and 0.450, with a 
mean value of 0.438. At the time of detection of proarrhythmic 
effects, QTc values were markedly prolonged and varied 
between 0.450 and 0.475, with a mean value of 0.465 (p = 
0.04). Except for one patient, all observed proarrhythmic 
effects occurred shortly after initiation of sotalol treatment and 
during the initial hospital stay (Table 3). 
In three more patients (all with atrial f utter after previous 
operation for congenital heart disease), the Holter ECG 
showed newly observed frequent monomorphic premature 
ventricular contractions (30 to 70/h) that spontaneously re- 
solved within 1 to 2 weeks despite maintenance ofdosage. The 
occurrence of transient frequent premature ventricular con- 
tractions was not considered relevant, and these patients were 
not counted as patients with proarrhythmia. 
Systemic side effects. In two patients, otalol treatment had 
to be discontinued because of symptoms of arterial hypoten- 
sion (fatigue and dizziness). 
No significant influence of sotalol on left ventricular func- 
tion as evaluated by echocardiography was detected; in two 
patients with left ventricular dilation as a result of sustained 
tachycardia before the administration of sotalol, left ventricu- 
lar function normalized under sotalol treatment. 
No patient showed evidence of impaired liver or renal 
function. 
Discuss ion  
Sotalol e~cacy. Sotalol proved to be a very effective drug 
in the treatment of various arrhythmias in pediatric patients. 
Sotalol was most effective in the prevention of recurrences of
supraventricular reentrant achycardias, and it was equally 
effective in patients with or without pre-excitation. In this 
group of patients, arrhythmias in 93% of treated children were 
successfully controlled with oral sotalol. These results are in 
accordance with previously reported success rates in infants 
(11) and children (12) and with experience in adult patients 
(10). 
Atrial flutter in childhood occurs predominantly after car- 
diac surgery, and in this setting it is associated with consider- 
able morbidity and mortality (20). In our group of children, 
sotalol completely prevented recurrences in 48% of treated 
patients. This success rate compares well with the results 
achieved with other drugs in the largest series published so far 
on childhood atrial flutter (21). 
Success rate was lowest in children with ventricular tachy- 
cardia. This finding is in accord with the results of the only 
pediatric study on sotalol that involved children with ventric- 
ular tachycardia (12). Only a few children with ventricular 
tachycardias receiving sotalol have been reported so far; thus, 
its value cannot be definitely determined. For adult patients 
the Electrophysiologic Study Versus Electrocardiographic 
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Monitoring (ESVEM) trial (6) showed that among seven 
antiarrhythmic drugs tested, only sotalol was associated with a 
significant reduction in the risk of ventricular tachycardia 
recurrence. 
ECG effects. Prolongation of the QT interval on the sur- 
face ECG is an expected finding in patients receiving oral 
sotalol, and this effect results from the class III antiarrhythmic 
properties of sotalol (22). In the present series a significant 
influence of sotalol dosage on QTc prolongation was observed, 
and a linear relation between incremental dosage and QTc 
prolongation could be shown. 
Systemic adverse ea'ects. The beta-blocking action of so- 
talol was well tolerated by most patients. This observation is in 
accord with the results of experimental studies (23) in which 
sotalol showed less pronounced hemodynamic effects than 
propranolol. Systemic side effects such as dizziness and fatigue 
led to discontinuation of the drug in two patients (3%) in the 
present study. In those patients in whom the effect of sotalol on 
heart rate could be assessed, the influence on maximal heart 
rate was more pronounced than on bradycardia. 
Proarrhythmia. Proarrhythmic effects are a constant find- 
ing in studies on sotalol in adult patients. In most series a rate 
of proarrhythmia of 3% to 5% was reported (5,24-26), and 
occasionally this rate was as high as 7% (3). The most striking 
finding of the present study is the considerable number of 
proarrhythmic events in children, In previously published 
studies on sotalol therapy in pediatric patients, proarrhythmic 
effects were not systemically evaluated. By use of daily stan- 
dard ECG and serial Holter monitors during the initial in- 
hospital phase of sotalol therapy, proarrhythmia w s found in 
7 (10%) of 71 treated patients. These proarrhythmic events led 
to discontinuation f the drug (four patients), dose reduction 
(two patients) and emergency pacemaker implantation (one 
patient). 
Consistent with reports on adult patients, all but one of the 
proarrhythmic effects were observed during the arly in- 
hospital phase of sotalol treatment. In contrast to studies in 
adult patients (26), no clear dose relation of proarrhythmia w s 
seen in our pediatric patients. In adult patients there is 
evidence for a relation between OTc prolongation and the 
incidence of proarrhythmia (24,25). Because reliable QTc 
measurements could be obtained in only four of the patients 
with proarrhythmia, this relation cannot be conclusively eval- 
uated in the present study, but there seems to be a trend 
toward more pronounced OTc prolongation in those four 
children. The increased risk of proarrhythmia s not solely 
dependent on QT prolongation (27), but the findings of the 
present study indicate that the effect of sotalol administration 
on the QT interval should be studied carefully during initiation 
of sotalol therapy. 
In three additional children, newly observed transient pre- 
mature ventricular contractions (30 to 70/h) were observed 
within 3 days of sotalol initiation. Because these effects were 
only transient and did not require therapeutic ntervention, 
such as drug discontinuation r dose reduction, these children 
were not counted as patients with proarrhythmia in the present 
study. These patients had close ECG monitoring and a pro- 
longed initial hospital stay untilthe transient nature of these 
effects became clear. It clearly may be debated whether 
frequent premature ventricular contractions are a problem in 
this setting. Concern was raised by the finding that in the 
patient with torsade de pointes, an ECG 2 weeks before the 
onset of the torsade showed newly observed asymptomatic 
premature ventricular contractions (bigeminy). 
It is ditficult to explain the difference in the rate of 
proarrhythmia between the present pediatric series and results 
in adults. The definition for proarrhythmia is the same as that 
used in studies on adult patients (18,25,26). One possible 
explanation for this excess incidence of proarrhythmia might 
be the considerable proportion of patients in the present series 
who previously had undergone intracardiac repair for congen- 
ital heart disease. These patients may show impaired AV 
conduction i response to antiarrhythmic drug therapy, as was 
observed in two patients in the present series. 
Clinical implications. The results of the present study 
suggest hat sotalol is a valuable antiarrhythmic drug in 
pediatric patients. It is of special value in the long-term 
treatment of symptomatic recurrent episodes of supraventric- 
ular reentrant tachycardia. Its effect on atrial flutter is less 
pronounced, but the success rate is high enough to consider the 
drug a valuable treatment option. Its value in the treatment of
childhood ventricular t chycardia remains to be determined 
because results in only a few patients have been published to 
date. 
The high rate of proarrhythmia requires initiation of treat- 
ment on an inpatient basis. The effect of sotalol administration 
on the QT interval should be observed, and close follow-up by 
serial Holter monitoring is mandatory. 
Conclusions. Sotalol seems to be a valuable new drug for a 
wide variety of arrhythmias in the pediatric age group. The 
drug is usually well tolerated, but its use is associated with a 
significant rate of proarrhythmia. 
We are indebted to Hartmut Hecker, PhD, Institute of Biometrics and Statistics 
of the Hannover Medical School, f r help in the statistical evaluation of the data. 
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